Skip to main content
SpringerLink
Log in

Role of Erlotinib in the Treatment of Non-Small Cell Lung Cancer

Clinical Outcomes in Wild-Type Epidermal Growth Factor Receptor Patients

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Erlotinib is an orally administered small molecule inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150 mg is approved for the treatment of unselected chemorefractory advanced non-small cell lung cancer patients as well as maintenance therapy after first-line chemotherapy. The European Medicines Agency has recently also approved erlotinib as the first-line therapy in patients with EGFR mutations. Although recent studies have identified higher response rates and improved survival with erlotinib in a subset of patients with EGFR mutations, the survival benefit from single agent erlotinib in chemorefractory patients and in the maintenance setting is well observed in EGFR wild-type patients. The role of single agent erlotinib in the first-line setting in special subsets of EGFR wild-type patients (elderly, poor performance status, non-smokers) needs to be further determined. The combination of erlotinib with other targeted therapies has shown promising results and warrants further studies in EGFR wild-type patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96

    Article  PubMed  Google Scholar 

  2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350: 379–92

    Article  PubMed  CAS  Google Scholar 

  3. Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001; 19: 1734–42

    PubMed  CAS  Google Scholar 

  4. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787–99

    Article  PubMed  CAS  Google Scholar 

  5. Gridelli C, Maione P, Bareschino MA, et al. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. Anticancer Res 2010 Apr; 30(4): 1301–10

    PubMed  CAS  Google Scholar 

  6. Davies RL, Grosse VA, Kucherlapati R, et al. Genetic analysis of epidermal growth factor action: Assignment of human epidermal growth factor receptor gene to chromosome 7. Proc Natl Acad Sci U S A 1980; 77: 4188–92

    Article  PubMed  CAS  Google Scholar 

  7. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159–67

    Article  PubMed  CAS  Google Scholar 

  8. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160–74

    Article  PubMed  CAS  Google Scholar 

  9. Perez-Soler R. HER1/EGFR targeting: refining the strategy. Oncologist 2004; 9: 58–67

    Article  PubMed  CAS  Google Scholar 

  10. Ling YH, Li T, Yuan Z, et al. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol Pharmacol 2007 Aug; 72(2): 248–58

    Article  PubMed  CAS  Google Scholar 

  11. Ling YH, Lin R, Perez-Soler R. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol Pharmacol 2008 Sep; 74(3): 793–806

    Article  PubMed  CAS  Google Scholar 

  12. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 May 20; 350(21): 2129–39

    Article  PubMed  CAS  Google Scholar 

  13. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–500

    Article  PubMed  CAS  Google Scholar 

  14. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306–11

    Article  PubMed  CAS  Google Scholar 

  15. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009 Aug; 28 Suppl. 1: S24–31

    Article  PubMed  CAS  Google Scholar 

  16. Ahn MJ, Park BB, Ahn JS, et al. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res 2008 Jun 15; 14(12): 3860–6

    Article  PubMed  CAS  Google Scholar 

  17. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958–67

    Article  PubMed  CAS  Google Scholar 

  18. Perez-Soler R. Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer. Clin Cancer Res 2007 Aug 1; 13(15 Pt 2):s4589–92

    Article  PubMed  Google Scholar 

  19. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al., National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 Jul 14; 353(2): 123–32

    Article  PubMed  CAS  Google Scholar 

  20. Bezjak A, Tu D, Seymour L, et al., National Cancer Institute of Canada Clinical Trials Group Study BR.21. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006 Aug 20; 24(24): 3831–7

    Article  PubMed  CAS  Google Scholar 

  21. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer — molecular and clinical predictors of outcome. N Engl J Med 2005 Jul 14; 353(2): 133–44

    Article  PubMed  CAS  Google Scholar 

  22. Reck M, van Zandwijk N, Gridelli C, et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol 2010 Oct; 5(10): 1616–22

    Article  PubMed  Google Scholar 

  23. Spigel DR, Lin M, O’Neill V, et al. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. Cancer. 2008 Jun 15; 112(12): 2749–55

    Article  PubMed  CAS  Google Scholar 

  24. Yoshioka H, Hotta K, Kiura K, et al., Okayama Lung Cancer Study Group. A phase II trial of erlotinibmonotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J ThoracOncol. 2010 Jan; 5(1): 99–104

    Google Scholar 

  25. Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012; Jan 24 [Epub ahead of print]

    Google Scholar 

  26. Fidias P, Novello S. Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010 Dec 1; 28(34): 5116–23. Epub 2010 Nov 1. Review

    Article  PubMed  Google Scholar 

  27. Cappuzzo F, Ciuleanu T, Stelmakh L, et al., SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010 Jun; 11(6): 521–9. Epub 2010 May 20

    Article  PubMed  CAS  Google Scholar 

  28. Brugger W, Kim JH, Hansen O, et al. Biomarker analyses from SATURN, a phase III placebo-controlled study of erlotinib as first-line maintenance therapy for advanced NSCLC. Eur J Cancer Supplements 2009; 7(2): 559 (abstr P-9176)

    Article  Google Scholar 

  29. Amann JM, Lee JW, Roder H, et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 2010 Feb; 5(2): 169–78

    Article  PubMed  Google Scholar 

  30. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients > or=70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007 Mar 1; 25(7): 760–6

    Article  PubMed  CAS  Google Scholar 

  31. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008 Mar 20; 26(9): 1472–8

    Article  PubMed  CAS  Google Scholar 

  32. Janne PA, Wang XF, Socinski MA, et al. Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. J Clin Oncol 2010; 28: 15s (suppl; abstr 7503)

    Google Scholar 

  33. Hesketh PJ, Chansky K, Wozniak AJ, et al. Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol 2008 Sep; 3(9): 1026–31

    Article  PubMed  Google Scholar 

  34. Lee S, Rudd R, Khan I, et al. TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy. J Clin Oncol 2010; 28: 15s (suppl; abstr 7504)

    Google Scholar 

  35. Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008 Feb 20; 26(6): 863–9

    Article  PubMed  CAS  Google Scholar 

  36. Kasahara K, Arao T, Sakai K, et al. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma. Clin Cancer Res 2010 Sep 15; 16(18): 4616–24

    Article  PubMed  CAS  Google Scholar 

  37. Yap TA, Olmos D, Brunetto AT, et al. Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies. J Clin Oncol 2011, 29(10): 1271–9. Epub 2011 Mar 7

    Article  PubMed  CAS  Google Scholar 

  38. Schiller JH, Akerley WL, Brugger W, et al. Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28: 18s (suppl; abstr LBA7502)

    Article  Google Scholar 

  39. Hughes AN, O’Brien ME, Petty WJ, et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009 Mar 10; 27(8) 1220–6

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, USA

    Bilal Piperdi & Roman Perez-Soler

Authors
  1. Bilal Piperdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roman Perez-Soler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bilal Piperdi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Piperdi, B., Perez-Soler, R. Role of Erlotinib in the Treatment of Non-Small Cell Lung Cancer. Drugs 72 (Suppl 1), 11–19 (2012). https://doi.org/10.2165/1163018-S0-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/1163018-S0-000000000-00000

Keywords

Search

Navigation